Chief Technology Officer
Michael Benchimol brings expertise in the manufacture of nanomedicines as well as ultrasound physics and its application in medicine. He has presented his work at the National Cancer Institute and Acoustical Society of America meetings and his work was featured on the cover of Journal of Controlled Release. Dr. Benchimol holds a B.S. in Electrical Engineering from Boston University and completed his Ph.D. and post-doc at UC San Diego where his dissertation focused on ultrasound responsive particles for cancer therapeutics.
Chief Financial Officer
David Renas has more than 25 years of financial, legal and business experience in the life science and healthcare sectors. Prior to joining Sonrgy, Mr. Renas served as Chief Financial Officer and General Counsel of Sangart, Inc., a biopharmaceutical company focused on the development of oxygen therapeutics. Earlier in his career Mr. Renas practiced corporate and securities law at Gray Cary Ware & Freidenrich (now DLA Piper) and Foley & Lardner. Mr. Renas began his career as a Certified Public Accountant at Deloitte Haskins & Sells, during which time he also served as an accounting instructor at San Diego State University. Mr. Renas holds a Bachelor of Arts degree in Economics from Stanford University and a Juris Doctorate from the University of California at Davis.
Michael Newman has over 25 years of experience participating in and managing oncology drug discovery and early drug development programs in academia, pharmaceutical and biotechnology companies. His experience spans small molecule, RNAi and biologic-based therapeutics, including immunotherapy, nanotechnology and targeted drug delivery. Dr. Newman has served as a consultant for over 20 companies, assisting with program identification and evaluation, management of R&D, fundraising, and in/out-licensing. In addition, his previous positions include faculty appointments in Biochemistry at Brandeis University and the Roche Institute of Molecular Biology, Senior Associate Director of Oncology at Sandoz Pharmaceuticals (world-wide head of cancer biology), Executive Director of Oncology at Novartis Pharmaceuticals (head of cancer biology in the US), Vice President of Biology at Ontogen Corporation, Chief Scientific Officer and Vice President of Research at Dihedron Corporation, Executive Vice President, Oncology at HUYA Bioscience International, and Executive Vice President of R&D at Vaxiion Therapeutics. Dr. Newman received a bachelor’s degree in Biology from the University of California at San Diego, a Ph.D. in Medical Sciences from Harvard Medical School (National Science Foundation Pre-doctoral Fellow) and carried out post-doctoral research at Cornell University. He is an author on over 30 publications and an inventor on over 17 patent applications.
Chief Commercial Officer
Clive Bertram brings over twenty years of commercial experience in the pharmaceutical industry. Prior to Sonrgy, Mr Bertram served for 5 years as Chief Commercial Officer of Sangart Inc. Prior to that he served as Senior Director of International Marketing at Pharmion Corp. leading the launch strategies for three oncology products. Earlier in his career he has held senior commercial roles at Chiron Corp., Celltech and Eli Lilly. Mr Bertram brings operational experience across all aspects of the commercial mix and product lifecycle from early disease strategy through development and launch to established brands to end of product lifecycle/patent loss.